Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

NCT05874414 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Cholangiocarcinoma

Interventions

DRUG: GNS561 + Trametinib

Sponsor

Genfit